We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Penwest Pharmaceuticals CO. (MM) | NASDAQ:PPCO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.00 | 0 | 01:00:00 |
Watson Pharmaceuticals Inc. (WPI) said it became the latest drug maker to win a license to sell a generic version of Opana extended-release pain-relief tablets in coming years after a patent dispute settlement with Endo Pharmaceuticals Holdings Inc. (ENDP).
Opana ER has been a source of continuing patent litigation for the developers. Endo and Penwest Pharmaceuticals Co. (PPCO) earlier this year agreed to grant separate licenses for Novartis AG's (NVS, NOVN.VX) Sandoz Inc. unit and Impax Laboratories Inc. (IPXL) to sell generic versions of the drug in 2012 and 2013, respectively.
Watson will have the right to launch its version--at various dosing levels--starting in September 2012, it said.
Sales for the Opana franchise rose 34% in the latest quarter for Endo to $73.8 million.
Opana ER is used to relieve moderate to severe pain in patients requiring around-the-clock treatment for an extended period of time, according to a website for the drug.
Watson shares closed Wednesday at $44.25 while Endo finished at $34.14. Neither was active premarket.
-By Matt Jarzemsky, Dow Jones Newswires; 212-416-2240; matthew.jarzemsky@dowjones.com
1 Year Penwest Chart |
1 Month Penwest Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions